1.

Medication status the Gulf FH cohort, stratified by the Dutch Lipid Clinic Network (DLCN) criteria.

2.

Medication status the Gulf FH cohort, stratified by the Dutch Lipid Clinic Network (DLCN) criteria.

1.

Baseline and post-treatment lipid profiles for the Gulf FH cohort, stratified by Dutch Lipid Clinic Network criteria (DLCN).

2.

Baseline and post-treatment lipid profiles for the Gulf FH cohort, stratified by Dutch Lipid Clinic Network criteria (DLCN).

1.

Demographic characteristics and comorbidities of patients with probable or definite FH at baseline.

2.

Demographic characteristics and comorbidities of patients with probable or definite FH at baseline.

1.

Pharmacological management and clinical outcomes of patients with probable or definite FH, at baseline and at 6-month of follow-up.

2.

Pharmacological management and clinical outcomes of patients with probable or definite FH, at baseline and at 6-month of follow-up.

1.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

2.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

3.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

4.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

5.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

6.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

7.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

8.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

9.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

1.

Colistin use per farm expressed as TiDDDVet.

2.

Colistin use per farm expressed as TiDDDVet.

3.

Colistin use per farm expressed as TiDDDVet.

4.

Colistin use per farm expressed as TiDDDVet.

5.

Colistin use per farm expressed as TiDDDVet.

6.

Colistin use per farm expressed as TiDDDVet.

7.

Colistin use per farm expressed as TiDDDVet.

8.

Colistin use per farm expressed as TiDDDVet.

9.

Colistin use per farm expressed as TiDDDVet.

1.

Sequenced isolates and their phenotypic and genotypic characteristics.

2.

Sequenced isolates and their phenotypic and genotypic characteristics.

3.

Sequenced isolates and their phenotypic and genotypic characteristics.

4.

Sequenced isolates and their phenotypic and genotypic characteristics.

5.

Sequenced isolates and their phenotypic and genotypic characteristics.

6.

Sequenced isolates and their phenotypic and genotypic characteristics.

7.

Sequenced isolates and their phenotypic and genotypic characteristics.

8.

Sequenced isolates and their phenotypic and genotypic characteristics.

9.

Sequenced isolates and their phenotypic and genotypic characteristics.

1.

Genomes used as reference for the detection of mutations linked to colistin resistance.

2.

Genomes used as reference for the detection of mutations linked to colistin resistance.

3.

Genomes used as reference for the detection of mutations linked to colistin resistance.

4.

Genomes used as reference for the detection of mutations linked to colistin resistance.

5.

Genomes used as reference for the detection of mutations linked to colistin resistance.

6.

Genomes used as reference for the detection of mutations linked to colistin resistance.

7.

Genomes used as reference for the detection of mutations linked to colistin resistance.

8.

Genomes used as reference for the detection of mutations linked to colistin resistance.

9.

Genomes used as reference for the detection of mutations linked to colistin resistance.

1.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

2.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

3.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

4.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

5.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

6.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

7.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

8.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

9.

Alterations in mgrB or its promoter region in Escherichia coli , Enterobacter spp. and Klebsiella spp.

1.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

2.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

3.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

4.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

5.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

6.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

7.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

8.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).

9.

Single alteration leading to colistin resistance (no other mutations in PmrAB and PhoPQ detected).